Movement Alert｜AKESO Rises 3.04% in Regular Trading, Innovative Drug Sector Collectively Strengthens Ahead of Major Academic Conferences

Market Focus08-05 14:59

On August 5, AKESO rose 3.04% in regular trading, trading at 96.6 HKD/share, with turnover of HKD 392 million. The gain was primarily driven by broad-based strength across the innovative drug sector.

On the news front, the innovative drug sector saw collective gains, with peers including Innovent Bio up 4.96%, BeiGene up 3.25%, and KEYMED Bio up 3.94%. The sector is being catalyzed by expectations of key clinical data disclosures at major academic conferences scheduled for the second half, including WCLC, ESMO, and ASH, which are drawing investor attention back to pipeline readouts and commercialization progress.

Supporting the broader positive sentiment, AKESO's global partner Summit recently updated overall survival data from the Phase III HARMONi study for ivonescimab, showing the hazard ratio improved to 0.76 in Western patients, substantively validating cross-ethnic efficacy consistency. The company also initiated first-patient dosing in a Phase II trial combining its novel Trop2/Nectin-4 bispecific ADC (AK146D1) with ivonescimab for advanced NSCLC, further expanding its pipeline depth.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1149383350?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 14:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149383350","market":"us","top_or_hot":-1,"title":"Movement Alert｜AKESO Rises 3.04% in Regular Trading, Innovative Drug Sector Collectively Strengthens Ahead of Major Academic Conferences","media":"Market Focus","content":"<p><p>On August 5, AKESO rose 3.04% in regular trading, trading at 96.6 HKD/share, with turnover of HKD 392 million. The gain was primarily driven by broad-based strength across the innovative drug sector.</p><p>On the news front, the innovative drug sector saw collective gains, with peers including Innovent Bio up 4.96%, BeiGene up 3.25%, and KEYMED Bio up 3.94%. The sector is being catalyzed by expectations of key clinical data disclosures at major academic conferences scheduled for the second half, including WCLC, ESMO, and ASH, which are drawing investor attention back to pipeline readouts and commercialization progress.</p><p>Supporting the broader positive sentiment, AKESO's global partner Summit recently updated overall survival data from the Phase III HARMONi study for ivonescimab, showing the hazard ratio improved to 0.76 in Western patients, substantively validating cross-ethnic efficacy consistency. The company also initiated first-patient dosing in a Phase II trial combining its novel Trop2/Nectin-4 bispecific ADC (AK146D1) with ivonescimab for advanced NSCLC, further expanding its pipeline depth.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜AKESO Rises 3.04% in Regular Trading, Innovative Drug Sector Collectively Strengthens Ahead of Major Academic Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜AKESO Rises 3.04% in Regular Trading, Innovative Drug Sector Collectively Strengthens Ahead of Major Academic Conferences\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-05 14:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 5, AKESO rose 3.04% in regular trading, trading at 96.6 HKD/share, with turnover of HKD 392 million. The gain was primarily driven by broad-based strength across the innovative drug sector.</p><p>On the news front, the innovative drug sector saw collective gains, with peers including Innovent Bio up 4.96%, BeiGene up 3.25%, and KEYMED Bio up 3.94%. The sector is being catalyzed by expectations of key clinical data disclosures at major academic conferences scheduled for the second half, including WCLC, ESMO, and ASH, which are drawing investor attention back to pipeline readouts and commercialization progress.</p><p>Supporting the broader positive sentiment, AKESO's global partner Summit recently updated overall survival data from the Phase III HARMONi study for ivonescimab, showing the hazard ratio improved to 0.76 in Western patients, substantively validating cross-ethnic efficacy consistency. The company also initiated first-patient dosing in a Phase II trial combining its novel Trop2/Nectin-4 bispecific ADC (AK146D1) with ivonescimab for advanced NSCLC, further expanding its pipeline depth.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1149383350","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149383350","pubTimestamp":1785913177,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 5, AKESO rose 3.04% in regular trading, trading at 96.6 HKD/share, with turnover of HKD 392 million. The gain was primarily driven by broad-based strength across the innovative drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"走势提醒|AKESO常规交易上涨3.04%，创新药板块在重大学术会议召开前集体走强","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On August 5, AKESO rose 3.04% in regular trading, trading at 96.6 HKD/share, with turnover of HKD 392 million. The gain was primarily driven by broad-based strength across the innovative drug sector.On the news front, the innovative drug sector saw collective gains, with peers including Innovent Bio up 4.96%, BeiGene up 3.25%, and KEYMED Bio up 3.94%. The sector is being catalyzed by expectations of key clinical data disclosures at major academic conferences scheduled for the second half, including WCLC, ESMO, and ASH, which are drawing investor attention back to pipeline readouts and commercialization progress.Supporting the broader positive sentiment, AKESO's global partner Summit recently updated overall survival data from the Phase III HARMONi study for ivonescimab, showing the hazard ratio improved to 0.76 in Western patients, substantively validating cross-ethnic efficacy consistency. The company also initiated first-patient dosing in a Phase II trial combining its novel Trop2/Nectin-4 bispecific ADC (AK146D1) with ivonescimab for advanced NSCLC, further expanding its pipeline depth.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1149383350","isCrawlerRequest":true}